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Purpose—Discovery of single nucleotide polymorphisms (SNPs) that predict a patient's risk of
docetaxel-induced neuropathy would enable treatment individualization to maximize efficacy and
avoid unnecessary toxicity. The objectives of this analysis were to discover SNPs associated with
docetaxel-induced neuropathy and mechanistically validate these associations in preclinical
models of drug-induced neuropathy.

Author Manuscript

Experimental Design—A genome-wide association study was conducted in metastatic castrateresistant prostate cancer patients treated with docetaxel, prednisone and randomized to
bevacizumab or placebo on CALGB 90401. SNPs were genotyped on the Illumina
HumanHap610-Quad platform followed by rigorous quality control. The inference was conducted
on the cumulative dose at occurrence of grade 3+ sensory neuropathy using a cause-specific
hazard model that accounted for early treatment discontinuation. Genes with SNPs significantly
associated with neuropathy were knocked down in cellular and mouse models of drug-induced
neuropathy.
Results—498,081 SNPs were analyzed in 623 Caucasian patients, 50 (8%) of whom experienced
grade 3+ neuropathy. The 1000 SNPs most associated with neuropathy clustered in relevant
pathways including neuropathic pain and axonal guidance. A SNP in VAC14 (rs875858) surpassed
genome-wide significance (p=2.12×10-8 adjusted p=5.88×10-7). siRNA knockdown of VAC14 in
stem cell derived peripheral neuronal cells increased docetaxel sensitivity as measured by
decreased neurite processes (p=0.0015) and branches (p<0.0001). Prior to docetaxel treatment
VAC14 heterozygous mice had greater nociceptive sensitivity than wild-type litter mate controls
(p=0.001).
Conclusions—VAC14 should be prioritized for further validation of its potential role as a
predictor of docetaxel-induced neuropathy and biomarker for treatment individualization.

Author Manuscript
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Introduction

Author Manuscript

The taxane class includes three US Food and Drug Administration (FDA)-approved
chemotherapeutic agents, paclitaxel, docetaxel and cabazitaxel, that have activity in a variety
of solid tumors including lung, breast, ovarian, gastric, and prostate cancers. Taxanes bind to
and stabilize microtubules, ultimately inhibiting the mitotic phase of cell cycle
development(1). The taxanes and other microtubule-targeting chemotherapeutic agents (e.g.,
vinca alkaloids) commonly induce peripheral neuropathy of varying severity(2).
Chemotherapy-induced peripheral neuropathy (CIPN) often presents as a combination of
paresthesia and dysesthesia, and can progress to irreversible loss of balance and dexterity
with continued treatment(3). Due to the progressive nature of the toxicity and its potential
effect on long-term quality of life(4), CIPN can necessitate treatment discontinuation, even
in the context of active tumor control.
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Patient demographic (i.e., race and history of neuropathy) and treatment (i.e., cumulative
dose and drug exposure) factors have been associated with CIPN(5-8), but there are
currently no effective methods for predicting CIPN risk and/or severity. Genome-wide
association studies (GWAS) of paclitaxel and vincristine-induced CIPN confirm that genetic
variation modifies patients' risk(9-12). The discovery and validation of single nucleotide
polymorphisms (SNPs) that influence risk of docetaxel-induced peripheral neuropathy
would be of clinical benefit, enabling identification of high-risk patients in whom taxane use
should be avoided if possible. SNPs that modulate risk of docetaxel-induced neuropathy
have been reported from candidate gene studies(13-15); however, no study has taken a
genome-wide approach. Based on the previous success of GWAS in discovering SNPs that
affect paclitaxel-induced neuropathy, a similar analysis was conducted in a cohort of
docetaxel-treated patients to identify genetic predictors of docetaxel-induced neuropathy.
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GWAS was performed in a large, prospectively enrolled, chemotherapy-naive cohort of
metastatic castrate-resistant prostate cancer (mCRPC) patients who were treated with up to
two years of docetaxel and prednisone, with half randomized to concurrent
bevacizumab(16). As these metastatic patients are at high risk of early treatment
discontinuation due to disease progression and/or death, which precludes occurrence of
neuropathy, a competing-risks adjusted statistical model was utilized(17, 18). Following
discovery of a SNP that surpassed genome-wide significance, pharmacogenetic replication
between the results of a previously conducted GWAS of paclitaxel-induced neuropathy(9)
and this GWAS of docetaxel-induced neuropathy and mechanistic validation of that gene in
cellular and animal models were attempted to determine whether genetic predictors of CIPN
were similar between the taxanes and to potentially validate clinically useful genetic
predictors of docetaxel-induced sensory peripheral neuropathy

Author Manuscript

Methods
Patients and toxicity

Author Manuscript

Cancer and Leukeumia Group B (CALGB/Alliance) 90401 was a double-blinded phase III
trial that equally randomized men with hormone-refractory prostate cancer to receive
docetaxel and prednisone with or without bevacizumab for up to two years(16). All patients
enrolled in the CALGB 90401 parent study who provided IRB-approved informed consent
for a pharmacogenomic substudy (CALGB 60404) were eligible for this GWAS. Briefly,
patient eligibility included histologically documented adenocarcinoma of the prostate that
had progressed while the patient was on hormone deprivation therapy. Relevant exclusion
criteria included prior chemotherapy or anti-angiogenesis therapy or clinically significant
(grade 2+) peripheral neuropathy. Toxicity data were collected by the Alliance Statistics and
Data Center at each treatment cycle on standardized forms that mandated reporting of grade
3+ peripheral sensory neuropathy, as defined by National Cancer Institute Common Toxicity
Criteria for Adverse Events (NCI CTCAE) version 3.0. Additionally, one case was reported
as a grade 3 cranial neuropathy event described as “sensory-facial.” Only neuropathy that
was considered by the clinician to be possibly, probably, or definitely attributable to
treatment, and occurred within 30 days of docetaxel administration, was included in the
analysis.
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All patients received docetaxel 75 mg/m2 infused over 1 hour on day 1 of each 21-day cycle
with 8 mg oral dexamethasone 12, 3, and 1 hour prior to infusion. Patients on both arms also
received 5 mg oral prednisone twice daily and were randomized to 15 mg/kg bevacizumab
or placebo by intravenous infusion on day 1 of each cycle. Use of growth factor, aspirin,
anti-emetics and luteinizing-hormone releasing hormone agonists was under the discretion
of the treating physician. Docetaxel administration was held for neutropenia (absolute
neutrophil count <1,500 cells/mm3) and the dose was decreased in increments of 10 mg/m2
for hepatic dysfunction, neurotoxicity, gastrointestinal toxicity or febrile neutropenia. The
protocol mandated discontinuation of docetaxel treatment if the patient required more than
two docetaxel dose decreases or in the event of specific toxicities or confirmed cancer
progression.

Author Manuscript

Genotyping

Author Manuscript

A 10-mL sample of whole blood was collected from all patients enrolling on the
pharmacogenomic substudy prior to initiation of protocol treatment. Genotyping and genetic
quality control were similar to that previously reported in the CALGB 40101 GWAS(9).
Genotyping was performed on the HumanHap610-Quad Genotyping BeadChip (Illumina
Inc., CA, USA) at the RIKEN Center for Genomic Medicine (Yokohama City, Japan).
Genotype data is available at dbGap (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?study_id=phs001002.v1.p1) SNPs that were known indeterminate (n=4,106) or
unreliable loci (Tech Note: Infinium® Genotyping Data Analysis, 2007) and patients with
SNP call rate <95% were excluded. Eigensoft version 3.0 was used to visualize genetic
ancestry for the 790 evaluable patients to identify a genetic European population (n=623) in
which the analysis was conducted. Additional SNPs were excluded for low call rate (<99%),
low minor allele frequency (<0.05), p-value of Hardy-Weinberg distribution <10-8 or nonautosomal loci, leaving 498,081 SNPs for analysis (Supplementary Figure 1).
Cellular Sensitivity Experiments

Author Manuscript

Commercially available human induced pluripotent stem cell (iPSC)-derived peripheral
neurons (Peri.4U) were purchased from Axiogenesis (Cologne, Germany) and plated at 1 ×
104 cells/well in 100 μL media as per manufactures' instructions. Figure 3A illustrates the
scheme for this experiment. Dharmacon Accell technology (GE Dharmacon, Lafayette, CO,
USA) was applied at 4 hours post-plating using 1 μM human siVAC14 SMARTpool or the
non-targeting control (NTC). 24 hours later, transfection media was exchanged for media
containing 0.17% DMSO vehicle control and either docetaxel (LKT Laboratories Inc., St.
Paul, MN) or paclitaxel (Sigma-Aldrich, St. Louis, MO). The drugs were prepared in a
darkened hood by dissolving powder in 100% DMSO to obtain a stock solution of 58.4 mM.
Stock drug was serially diluted in media for final dosing concentrations ranging from 10 pM
to 1 μM, increasing by factors of ten. Control wells were treated with 0.17% final
concentration of DMSO to match drug treatments. After 24 or 48 hour drug treatments,
neurons were stained with 0.3 ng/mL Hoechst 33342 (Sigma-Aldrich) and 1.5 μg/mL
Calcein AM (Molecular Probes, Life Technologies Inc.) and imaged at 10× magnification
using an ImageXpress Micro imaging microscope (Molecular Devices, LLC, Sunnyvale,
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CA) at the University of Chicago Cellular Screening Center. Neurite changes were
determined by individual cell measurements of relative total neurite outgrowth, relative
number of processes, relative number of branches, mean/median/max process length,
relative cell body area, relative straightness and relative mean outgrowth intensity. The data
represents triplicate experiments making measurements on more than 1000 cells per
treatment as previously described(19). Two wells of transfected cells were collected per
timepoint using the Cells-to-Ct kit (Ambion, Life Technologies Inc., Carlsbad, CA) and
reversed transcribed as per kit instructions. Quantitative real time reverse transcription
polymerase chain reaction (qRT-PCR) was performed using Taqman primers (Fisher
Scientific LLC, Hanover Park, IL) for VAC14 (Hs00947931_m1) and compared to human
beta-2-microglobulin (NM_004048.2) housekeeping gene at 24, 48 and 72 hours posttransfection (as previously described; (19).

Author Manuscript

Mouse Sensitivity Experiments
Mice bred for VAC14 heterozygosity (VAC14+/-) and VAC14 wild-type litter mates
(VAC14+/+) on C57/BL6 background were obtained from Lois Weisman at University of
Michigan and acclimated to living conditions at University of Maryland(20). Mice 3-5
months of age were randomly assigned to docetaxel or placebo treatment, with 6-7 mice in
each treatment arm. The entire experiment was conducted separately in male and female
mice. Intraperitoneal administration of docetaxel 2 mg/kg or saline vehicle was administered
on days 1, 3, 5, and 7.

Author Manuscript

Behavioral testing for the development of increased mechanical sensitivity took place at
baseline (prior to treatment), day 5 (after two doses), day 8 (24 hours after the fourth dose),
and weekly for 3 additional assessments. Mechanical sensitivity was measured in mice from
both treatment arms simultaneously by a blinded individual using von Frey filaments, as
previously described(21). Briefly, mice were placed in individual Plexiglas® cubes on an
elevated wire mesh platform and allowed to acclimate for approximately one hour, when
grooming and exploration behaviors ended. A series of von Frey filaments (Touch Test
Sensory Evaluator Kit, myNeurolab.com, St. Louis, MO), with bending forces of 0.04-2.0 g,
were applied to the plantar surface of the left hind paw until the filament just bent and was
held in place for 5 seconds or until the mouse withdrew its paw. A positive response was
defined as a brisk withdrawal, with or without shaking or licking, of the hind paw during or
immediately upon removal of the filament application. Each filament was tested 5 times on
each hind paw starting with the 0.4 g filament. If the 0.4 g filament elicited 3 positive
responses out of 5 trials, then testing continued moving downward through the series to the
0.04 g filament and the number of withdrawals was recorded for each filament. If the 0.4 g
filament did not elicit 3 positive responses, then testing continued moving upward through
the series to the 2.0 g filament and the number of withdrawals was recorded for each
filament. Threshold was defined as the filament with the lowest bending force that elicited at
least 3 positive responses out of 5 trials.

Author Manuscript

Statistics
The primary endpoint for GWAS analysis was the cumulative docetaxel dose (mg/m2) at
first report of treatment-related grade 3+ sensory peripheral neuropathy. Patients who did not

Clin Cancer Res. Author manuscript; available in PMC 2017 October 01.

Hertz et al.

Page 6

Author Manuscript

complete two years of therapy due to progression/death, treatment-terminating adverse
event, or any other reason were informatively censored at the cumulative docetaxel dose
received; therefore, the statistical analysis was conducted within a competing-risk model
framework with the inference conducted on the basis of cause-specific hazard(17, 18).
Cumulative incidence curves were constructed to visualize the influence of each of the top
three hits with neuropathy incidence. The relationship between each SNP and neuropathy
was adjusted for clinical covariates with putative relevance to neuropathy risk: diabetes
(reported history of diabetes or current diabetes treatment vs. none), age (continuous), body
mass index (BMI) (≤ 30 kg/m2 vs. > 30 kg/m2), and treatment arm (bevacizumab vs.
placebo), regardless of whether the covariate was significantly associated with neuropathy in
this cohort.

Author Manuscript

Cross-study clinical replication of the SNP with the greatest association with neuropathy
was attempted in a cohort of Caucasian breast cancer patients treated with paclitaxel on the
CALGB 40101 clinical trial(22). GWAS of the cumulative paclitaxel dose at occurrence of
grade 2+ neuropathy has previously been published(9). Additionally, a SNP predictive of
paclitaxel-induced neuropathy risk (rs10771973, FGD4) discovered and replicated in the
CALGB 40101 GWAS was interrogated in the GWAS results from the docetaxel-treated
Caucasian patients on CALGB 90401 to assess whether the SNPs that influence neuropathy
risk are similar between the two taxanes.

Author Manuscript

Statistical analyses were performed by Alliance statisticians on a database locked on August
15, 2012. All analyses were conducted using the R [R]statistical environment version
3.1.1(23) or higher, using extension packages survival (version 2.37-7)(24), GenABEL
(version 1.8-0)(25), cmprsk (version 2.2-7)(26) and interval (version 1.1-0.1)(27). To search
for cumulative genetic effects, the genes that mapped to the top 1000 SNPs were included in
a pathway enrichment analysis using the Ingenuity Pathway Analysis version 17199142
(Ingenuity® Systems, Inc, www.ingenuity.com) internal algorithm. Peripheral neuronal cell
phenotypes (outgrowth, processes, branching, etc.) measured after treatment with increasing
docetaxel and paclitaxel concentrations were compared between VAC14 siRNA and nontargeted control siRNA using two-way ANOVA.

Author Manuscript

Mouse mechanical sensitivity thresholds were compared prior to docetaxel treatment
between VAC14+/+ and VAC14+/- mice using an interval-censored analysis with the
minimum fiber size inducing a response as the phenotype. The genotype groups in the
untreated mice were compared again on day 28. The same method was used to compare
sensitivity thresholds of docetaxel treated and untreated mice following treatment on day 8.
To assess whether VAC14+/- mice were more sensitive to docetaxel-induced changes in
mechanical stimuli, parametric survival regression was used to test for the effect of VAC14
by treatment interaction on withdrawal threshold on day 8, after treatment was completed.

Results
Genome-wide Association Study
The CALGB/Alliance 90401 parent study enrolled 1,050 patients, of whom 863 provided
consent and registered for the pharmacogenomics substudy CALGB 60604 (CALGB is now
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a part of the Alliance for Clinical Trials in Oncology). The GWAS included 790 patients, of
whom only the 616 self-reported, genetically defined Europeans receiving treatment were
included in the analysis to minimize confounding from population substructure
(Supplementary Figure 1). Demographic characteristics for the discovery cohort including
baseline covariates potentially relevant to treatment-induced neuropathy risk are reported in
Table 1. The median age was 69 years, body mass index (BMI) was 29 kg/m2, and 97
patients (16%) had a history of diabetes. Randomization was nearly even to the bevacizumab
(314 patients, 51%) and placebo (302, 49%) arms.

Author Manuscript

The overall incidence of grade 3+ sensory neuropathy was 8.1% (50/616). The 566 patients
who did not experience neuropathy were classified as having either completed treatment
without neuropathy (3.9%) or categorized based on their reason for discontinuation: death/
progression (41.1%), non-CIPN treatment terminating adverse event (30.2%) or withdrawal/
other (16.7%) (Supplementary Table 1). The risk of neuropathy was not significantly
different in the bevacizumab and placebo arms (p=0.11), which were pooled for analysis.

Author Manuscript

GWAS analysis was performed on the cumulative docetaxel dose (mg/m2) at first report of
treatment-induced grade 3+ sensory peripheral neuropathy (Figure 1). The ten most
significant SNPs, ranked according to the unadjusted p-value for cause-specific association
with neuropathy, are listed in Table 2 with rsID, gene annotation, and hazard ratios before
and after adjustment (Top 1000 SNPs in Supplementary Table 2). One SNP surpassed
Bonferonni-corrected significance (0.05/498,022=1.004×10-7). This is an intronic SNP in
the VAC14 gene (rs875858, minor allele frequency=0.056), which increased neuropathy risk
(HR=3.60, 95%CI: 2.21-5.84, p=2.12×10-8, Figure 2A). The second and third most strongly
associated SNPs were an intergenic SNP (rs11017056, MAF=0.223, HR=2.61, 95%CI:
1.77-3.84, p=3.84×10-7) and an intronic SNP in the ATP8A2 gene (rs1326116, MAF=0.194,
HR=2.77, 95%CI: 1.79-4.27, p=1.77×10-6), both of which increased neuropathy risk
(Figures 2B and 2C).

Author Manuscript

The associations of all SNPs were then adjusted for treatment arm and several clinical
covariates previously reported to be relevant to neuropathy risk including diabetes, age, and
BMI. In this particular cohort, among the clinical covariates only increasing age (p=0.0003)
was significantly associated with neuropathy, though increasing BMI showed a trend toward
association (p=0.05). Covariate adjustment did not substantially affect the results, though the
association of VAC14 fell below the Bonferonni-corrected significance threshold after
adjustment (p=5.88 ×10-7). The top 1000 SNPs mapped to 240 unique genes, which were
included in the pathway analysis. The three most significantly enriched pathways in the
GWAS are displayed in Supplementary Table 3. Notably, two of these enriched pathways are
relevant to CIPN; Axonal Guidance (p=1.20×10-4) and Neuropathic Pain Signaling in Dorsal
Horn Neurons (p=6.03×10-3).
Cross-GWAS Pharmacogenetic Replication
Due to the absence of a large cohort of docetaxel-treated patients with prostate cancer in
which to perform replication, and our interest in assessing whether taxanes share genetic
predictors of neuropathy risk, cross-study pharmacogenetic replication was attempted in a
cohort of paclitaxel-treated Caucasian patients with breast cancer enrolled on CALGB
Clin Cancer Res. Author manuscript; available in PMC 2017 October 01.
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(Alliance 40101). The VAC14 SNP (rs875858) discovered in our docetaxel-induced
neuropathy GWAS was not associated with paclitaxel-induced neuropathy in the 40101
study (p=0.70)(9). In addition, SNPs that were discovered in previously published GWAS of
paclitaxel-induced neuropathy (FGD4 (rs10771973) p=0.39, EPHA4 (rs17348202) p=0.76,
EPHA5 (rs7349683) p=0.15, intergenic (rs3125923) p=0.057, FCAMR (rs1856746) p=0.25)
(9, 10, 12) or candidate SNP studies of docetaxel-induced neuropathy (GSTP1 Ala114Val
(rs1138272) p=0.98, ABCB1 1236C>T (rs1128503) p=0.62, ABCB1 (rs4148738) p=0.90,
ABCB1 3435C>T (rs1045642) p=0.80) (13-15) were not associated with docetaxel-induced
neuropathy occurrence in the CALGB 90401 patients. Finally, when comparing the top
SNPs from taxane-induced neuropathy GWAS performed within CALGB 90401 (docetaxel)
and 40101 (paclitaxel), there was no statistical evidence that the degree of overlap was
greater than would be expected by random chance (data not shown).

Author Manuscript

Peripheral Neuronal Cell Sensitivity

Author Manuscript

To determine the effect of VAC14 knockdown on neuronal sensitivity to docetaxel and
paclitaxel, commercially available human iPSC-derived peripheral neurons (Peri4.U) were
utilized. At the time of image analysis, which is 24 and 48 hours post drug treatment (48 and
72 h post transfection), expression of VAC14 in neurons treated with 1 μM siRNA had
decreased to 54 and 44%, respectively, as compared to control cells treated with a nontargeting siRNA (Figure 3B). The VAC14 siRNA knockdown at 24 hours post-docetaxel
treatment did not affect relative total outgrowth (Figure 3C) in the peripheral neurons but
resulted in significantly greater sensitivity to docetaxel as measured by relative number of
processes (p=0.0015, Figure 3D) and relative number of branches (p<0.0001, Figure 3E)
Similar effects were found in preliminary studies of VAC14 knockdown in a human IPSCderived cortical neuron, iCell® Neurons measured 48 hours after treatment (Cellular
Dynamics International, Madison, WI) (data not shown). In contrast, VAC14 siRNA
knockdown significantly decreased peripheral neuronal cell sensitivity to paclitaxel as
measured by these same cellular phenotypes (all p<0.05, Figure 3F-3H). Other
morphological characteristics including mean process length, mean outgrowth intensity and
relative straightness were also measured for docetaxel and paclitaxel (Supplementary Figure
2). We found a decreased sensitivity to docetaxel and paclitaxel when measuring mean
process length and for mean outgrowth intensity for paclitaxel only. There was no difference
in measurements of relative straightness (data not shown).
Mouse Mechanical Sensitivity

Author Manuscript

Prior to receiving docetaxel treatment, VAC14+/- heterozygous mice were more sensitive
than wild type VAC14+/+ mice to mechanical stimuli using von Frey filaments (p=0.001,
Supplementary Figure 3). When stratified by gender this effect was significant in male mice
(p=0.002) but not female mice (p=0.16), however, there was no statistically significant
gender interaction (p=0.10). The difference in sensitivity to mechanical stimuli between
genotype groups at baseline was attenuated over the course of the experiment in untreated
mice, as there was no evidence of a difference between these groups from at the end of the
experiment (p=0.23). As expected, 8 days of docetaxel treatment increased sensitivity to
mechanical stimuli compared to untreated control mice, regardless of mouse genotype
(p<0.0001, Figure 4). Comparing across genotype groups, there was no difference between
Clin Cancer Res. Author manuscript; available in PMC 2017 October 01.
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VAC14+/- and VAC14+/+ mice in docetaxel-induced increase in threshold sensitivity to
mechanical stimuli at day 8 (p=0.18) or day 14 (p=0.80) when the neuropathy was at its
maximum.

Discussion

Author Manuscript
Author Manuscript

GWAS in a large cohort of mCRPC patients receiving docetaxel treatment identified an
intronic SNP (rs875858) within VAC14 that was associated with increase neuropathy risk
(HR=3.60). VAC14 has been directly linked to neurodegeneration in animal models(20) and
linked to hereditary neuropathy conditions in humans(28). The lack of clinical replication in
a cohort of paclitaxel-treated breast cancer patients is perhaps due to known differences
between the two taxanes, including neuropathy profile(29). Distinct genetic modifiers of
cellular sensitivity to paclitaxel and docetaxel have been previously reported in in vitro
models(30) and the results of cellular sensitivity experiments demonstrating that VAC14
knockdown enhances sensitivity of peripheral neurons to docetaxel but not paclitaxel for
relative number of processes and relative branching, further support this hypothesis. Given
the distinct genetic effects on neuronal sensitivity to docetaxel and paclitaxel it is
conceivable that the polymorphisms that affect neuropathy risk also differ between the two
taxanes. This would be consistent with the lack of cross-study replication, including the lack
of association with docetaxel-induced neuropathy occurrence in this analysis for SNPs
(FGD4, EPHA4 and EPHA5) that have been previously discovered, and in some cases
replicated, in paclitaxel-induced neuropathy GWAS (9, 10, 12, 31). Alternatively,
heterogeneity between the patient cohorts, including differences in gender, age, and
functional status, or differences in the phenotype (grade 2+ vs. grade 3+), may explain the
lack of replication across the clinical GWAS. This GWAS was also not able to replicate
previously reported associations between docetaxel-induced neuropathy and SNPs in
ABCB1(15) or GSTP1(13, 14) reported in previous candidate SNP studies, similar to the
failure of paclitaxel GWAS to replicate associations with candidate SNPs including
CYP2C8*3(32).
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The mechanistic importance of VAC14 in docetaxel-induced neuropathy was tested in two
pre-clinical models of CIPN. Knockdown of VAC14 in the peripheral neuronal cell model
(Peri.4U) increased sensitivity to docetaxel treatment as measured by decreased neurite
number of processes and neurite branching. Interestingly, knockdown of VAC14 seemed to
decrease cellular sensitivity to paclitaxel treatment for these morphological characteristics
suggesting that this gene may play an important role in the damage to processes and
branching induced by docetaxel but not paclitaxel. A similar model of human neuronal cell
sensitivity that utilizes induced pluripotent cortical neurons (iCell® Neurons) has previously
been used for mechanistic validation of GWAS hits that increases risk of paclitaxel-induced
neuropathy(19, 33) and vincristine-induced neuropathy(11). These human model systems
have several advantages over the use of rodent cell lines such as rat pheochromocytoma cell
lines, PC12 or NS1. One major limitation of rodent cell lines is the required treatment with
nerve growth factor to initiate nerve outgrowth, which confounds the evaluation of drug
treatment effects(34-36).
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To our knowledge this is the first study to attempt mechanistic validation of a finding from a
clinical GWAS in an animal model of CIPN. The Von Frey Filament Test is a wellestablished rodent model to test sensitivity to nociceptive stimuli, as a surrogate for
peripheral neuropathy, that is commonly used for mechanistic investigation of
neuropathy(21, 37, 38). Unlike the cell experiment, VAC14 heterozygous mice were not
more sensitive than wild-type littermates to the effect of docetaxel, but were more sensitive
to mechanical stimuli prior to treatment. The enhanced sensitivity in the heterozygous mice
at baseline was attenuated over time in the untreated cohort, in both male and female mice. It
is possible that these mice acclimate to the discomfort of the mechanical stimuli or they may
be experiencing numbness, another characteristic symptom of peripheral neuropathy in
taxane-treated patients, though additional experiments would be required to test either
hypothesis. It is unclear from these findings whether patients with VAC14 polymorphisms
have subclinical neuropathy at baseline that is expressed by treatment, as suggested by the
mouse data, or whether they are similar at baseline and have greater neuropathy
development from docetaxel treatment. Subjective testing that is sensitive for subclinical
neuropathy, perhaps with electrophysiological or quantitative sensory assessment(39), in
untreated patients with wild-type and polymorphic VAC14 may help resolve this
conundrum.
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The VAC14 protein provides a scaffold for the lipid kinase PIKfyve and its positive
regulator, FIG4. These proteins reside in a complex that is responsible for the generation of
the signaling lipids phosphatidylinositol (3,5)-bisphosphate (PI(3,5)P2) and PI5P. These
lipids are essential in multiple tissues(28). The inability of VAC14-/- homozygous mice to
survive beyond 1-2 days after birth necessitated the use of VAC14+/- heterozygous mice(20).
On autopsy AC14-/- homozygous mice exhibit massive neurodegeneration with cell bodies
in the central and peripheral nervous system containing large vacuoles. This
neurodegeneration and vacuolization are similar to that found in FIG4 null mice, suggesting
that variation in these genes is likely to phenocopy in humans as well as in mice(40). A rare
mutation in the FIG4 gene is known to cause a subtype of Charcot-Marie-Tooth disease, a
hereditary neuropathy syndrome(41). Interestingly, the CALGB 40101 paclitaxel-induced
neuropathy GWAS discovered and replicated an association for a SNP in FGD4
(rs10771973), another gene known to cause Charcot-Marie-Tooth disease(42), though this
variant was not associated with docetaxel-induced neuropathy in our CALGB 90401 cohort.
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The SNP (rs875858) discovered in this GWAS lies within an intron of the VAC14 gene. It is
unclear what effect, if any, this individual SNP has on VAC14 expression or activity in the
peripheral neuron. In the GTEx database there is no association between rs875858 and
VAC14 gene expression in the tibial nerve tissue, though the power of this analysis is limited
by the relatively small number of samples (n=256) and low minor allele frequency
(MAF=0.06) of this SNP http://www.gtexportal.org/home/eqtls/bySnp?
snpId=rs875858&tissueName=Nerve_Tibial. In the larger DGN cohort (n=922), rs875858 is
highly associated with IL34 (p=4e-7) expression in whole blood. IL-34 is structurally similar
to colony-stimulating factor 1 and both are ligands of the colony-stimulating factor 1
receptor(43), which has recently been identified as an efficacious target in mouse models of
Charcot-Marie-Tooth disease(44), providing an alternative plausible biological mechanism
for this association. Finally, it is conceivable that this SNP is not functionally relevant but
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instead is a genetic marker of a different causative SNP; however, rs875858 lies in a region
of low linkage disequilibrium.
The SNP (rs1326116) with the third strongest association with docetaxel-induced
neuropathy is an intronic polymorphism in the ATP8A2 gene, which encodes ATP8A2, a P4
ATPase. The P-type ATPases are a superfamily of proteins that translocate phospholipids
between the two leaflets of cellular lipid bilayers(45). Several lines of evidence link ATP8A2
to neurological development and function; in vitro data that ATP8A2 overexpression
enhances neurite outgrowth(46), animal data that ATP8A2 mutations cause overt progressive
neurodegeneration in Wabbler-lethal mice by disrupting axonal transport and polarity(47),
and case reports of ATP8A2 mutations causing severe neurological phenotypes in
patients(48, 49).
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The three pathways most highly enriched in the GWAS results include axonal guidance and
neuropathic pain signaling, both of which have obvious relevance to taxane-induced
peripheral neuropathy. Growth and maintenance of neuronal axons requires organization of
microtubules into a cytoskeleton(50). Taxanes stabilize microtubules, potentially interfering
with cytoskeletal organization leading to the overt neuropathic symptoms reported by
patients. Enrichment in a similar pathway, axonal outgrowth, was reported in a secondary
analysis of a paclitaxel-induced neuropathy GWAS, suggesting that these two studies are
identifying similar genetic signatures(51), despite the lack of overlap of individual SNPs in
the top 1000 hits. Neuropathic pain is one of the characteristic clinical manifestations of
taxane-induced neuropathy, in addition to sensory and motor components(2). Neuropathic
pain signaling in the dorsal horn neurons may contribute to taxane-induced peripheral
neuropathy via a higher propensity for development of central sensitization(52).
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The primary limitation of this study is the lack of availability of an independent clinical trial
cohort of docetaxel-treated patients for pharmacogenetic replication. Another limitation is
the reliance on the protocol-specified collection of severe peripheral neuropathy (grade 3 or
higher), rather than systematic collection across all toxicity grades. It is possible that some
patients experienced grade 2 neuropathy without progressing to grade 3, and thus were not
included as neuropathy events in this analysis. Furthermore, ordinal analysis across all
neuropathy grades (0-4) would have brought greater statistical power and may have
identified a distinct set of SNPs that predict neuropathy severity, similar to the paclitaxelinduced neuropathy GWAS findings in CALGB (Alliance) 40101(9). The lack of grade 1 or
2 neuropathy data collection may explain the absence of events in the patients homozygous
for the rs875858 SNP. However, two of these patients discontinued docetaxel treatment quite
early, after 6 (442 mg/m2) and 8 (561 mg/m2) cycles for progression and grade 3 nausea/
vomiting, respectively. The third patient was discontinued after 26 cycles (1,746 mg/m2) for
a constellation of grade 3 toxicities including cough, dyspnea, fatigue, febrile neutropenia,
and pneumonitis, without any documentation of peripheral neuropathy during treatment. The
collection of DNA and comprehensive baseline and outcomes data, including accurate
assessment of timing and severity of peripheral neuropathy, in other large clinical cohorts
will allow for independent replication of our findings.
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In conclusion, GWAS of a prospectively enrolled patient cohort identified a SNP in VAC14
that predicts sensitivity to docetaxel-induced peripheral neuropathy. VAC14 heterozygous
mice were subsequently shown to be more sensitive to nociceptive stimuli at baseline, and
peripheral neuronal cell (Peri.4U) sensitivity to docetaxel is enhanced after VAC14
knockdown, providing mechanistic validation of the relevance of VAC14 to docetaxelinduced neuropathy. However, the relatively low hazard ratio of this SNP suggests that no
single variant or gene is responsible for dictating neuropathy sensitivity or will be clinically
useful for personalizing docetaxel treatment. This is consistent with the multifactorial nature
of neuropathy that depends on both drug exposure and a variety of patient factors, including
age and BMI, which were associated with neuropathy occurrence in this cohort. Replication
of the influence of our top candidate SNPs on neuropathy risk in a similar clinical trial
cohort of docetaxel-treated mCRPC patients is of great interest to validate the role of these
genes and provide support for further investigation into this mechanism for chemotherapyinduced neuropathy prevention or treatment.
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Statement of Translational Relevance
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The taxanes are a class of chemotherapeutic agents that are commonly associated with
treatment-limiting peripheral sensory neuropathy. Genetic predictors of paclitaxelinduced neuropathy have been discovered but little is known about whether similar
genetic factors are associated with risk of docetaxel-induced neuropathy. Discovery of
genetic predictors of docetaxel-induced neuropathy could inform personalized treatment
decisions to maximize efficacy and avoid unnecessary toxicity. We conducted a genomewide association study in a large cohort of Caucasian men with hormone refractory
prostate cancer treated with docetaxel. One single nucleotide polymorphism in VAC14
that was significantly associated with docetaxel-induced neuropathy was then
mechanistically validated in cellular and animal models of neurotoxicity. These finding
suggest that distinct genetic variants influence risk of peripheral neuropathy from
paclitaxel and docetaxel. The genetic variant identified in this study could be useful for
understanding the mechanism of docetaxel-induced neuropathy and may be informative
for avoiding docetaxel treatment in patients at elevated neuropathy risk.
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Figure 1. Genome-wide association results

Manhattan plot displaying the unadjusted p-value for the association of cumulative docetaxel
dose at grade 3+ sensory neuropathy for all SNPs that passed quality control (n=498,022).
One SNP (rs875858) surpassed the Bonferonni-corrected significance threshold of 1.0×10-7.
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Figure 2. Incidence of Neuropathy by Genotype for Highly Associated SNPs

Cumulative incidence curve of docetaxel dose at grade 3+ neuropathy occurrence stratified
by genotype for the top three hits: A) a VAC14 intronic SNP (rs875858), B) an intergenic
SNP (rs11017056), and C) an ATP8A2 intronic SNP (rs1326116). In each case, carrying the
variant allele increased neuropathy risk compared to wild-type patients, though there were
too few patients who were homozygous for the rare VAC14 variant (n=3) to draw
meaningful conclusions in this group.
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Figure 3. VAC14 Knockdown increases neuronal cell sensitivity to docetaxel but decreases
sensitivity to paclitaxel
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A) Peripheral neuron (Peri.4U) experimental scheme illustrating timing of treatment and
imaging. B) Relative VAC14 expression at 24, 48 and 72 hours post-transfection with
siVAC14 compared to non-targeting control (NTC) produced a steady decline of VAC14
expression over time. The neurite outgrowth changes after 24 hours docetaxel (48 hours
knockdown) showed no significance as measured by C) total outgrowth but did result in
greater sensitivity to docetaxel in D) relative number of processes and E) relative number of
branches. Alternatively, VAC14 knockdown decreased peripheral neuronal cell sensitivity to
paclitaxel, 3F-3H. Open circle represent data from VAC14 siRNA and closed circle from
NTC siRNA. Neurite parameters measured with MetaXPress® software were averaged from
3 independent experiments. Error bars represent the standard error of the mean from three
independent transfection experiments. NTC = non-targeting control, UT= untransfected
control.
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Figure 4. Docetaxel Treatment Increases Nociceptive Sensitivity in VAC14 Heterozygous and
Wild-type Mice
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The withdrawal threshold is defined as the lightest fiber weight that caused each mouse to
withdraw their hind paw at least three times out of five. Each mouse has a withdrawal
threshold at each time-point in the study. The mean withdrawal threshold is the average of
12-14 mice (6-7 for each gender) for each treatment condition (VAC14 genotype and
docetaxel treatment). Docetaxel- treated mice of either genotype had greater hindpaw
withdrawal sensitivity following the end of treatment at day 8 compared to the untreated
control mice (p<0.0001). There was no significant difference in the docetaxel-induced
increase in withdrawal sensitivity comparing VAC14 heterozygous and wild-type mice
(p=0.18).
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Demographic Data for Patients Included in GWAS (n=616).
Median (years)

68.9

Range (years)

41.7-93.5

Age
Median

(kg/m2)

29.0

Body mass index
Range

(kg/m2)

16.1-53.3

Yes

97 (15.8%)

No

519 (84.3%)

Bevacizumab

314 (51.0%)

Placebo

302 (49.0%)

Diabetes

Treatment arm
Median

(mg/m2)

626

Cumulative docetaxel dose
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ECOG performance status

Disease type

Range (mg/m2)

72-2,942

0

340 (55.2%)

1

258 (41.9%)

2

18 (2.9%)

Measurable disease

310 (50.3%)
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9

2

rs2213920

rs4438470

228722963

117311405

132262880

3780179

25287298

226061042

4762807

25273046

131720630

69332956

Position

SPHKAP

Intergenic

OPCML

Intergenic

ATP8A2

KIAA1486

Intergenic

ATP8A2

Intergenic

VAC14

Gene

0.137

0.128

0.305

0.057

0.191

0.063

0.175

0.194

0.223

0.056

MAF

5.47E-06

5.26E-06

3.90E-06

3.63E-06

3.16E-06

2.62E-06

1.83E-06

1.77E-06

3.84E-07

2.12E-08

P-value

Adjusted for patient BMI, age, history of diabetes, and treatment arm.

*

95% CI: 95% Confidence interval around hazard ratio estimate
Chr: Chromosome
HR: Hazard ratio
MAF: minor allele frequency in the 90401 Caucasian cohort
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Chr

rsID

2.71

2.63

2.38

3.64

2.71

3.34

2.72

2.77

2.61

3.60

HR

1.73-4.25

1.70-4.06

1.62-3.48

2.03-6.52

1.75-4.18

1.95-5.71

1.78-4.17

1.79-4.27

1.77-3.84

2.21-5.84

95% CI
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7.79E-05

2.11E-05

2.41E-05

4.45E-05

9.26E-06

3.26E-05

2.51E-05

4.57E-06

6.36E-07

5.88E-07

P-value

2.47

2.66

2.32

3.41

2.90

3.19

2.49

2.99

2.58

3.85

HR

Adjusted*
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